New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
04:55 EDTDHR, DHR, DHR, TEVA, TEVA, TEVA, GMED, GMED, GMED, RHHBY, RHHBY, RHHBY, MDCO, MDCO, MDCO, NVO, NVO, NVO, GILD, GILD, GILD, OMI, OMI, OMI, PKI, PKI, PKI, WCG, WCG, WCG, BDX, BDX, BDXGoldman to hold a conference
35th Annual Global Healthcare Conference to be held in Rancho Palos Verdes, California on June 10-12.
News For DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX From The Last 14 Days
Check below for free stories on DHR;WCG;PKI;OMI;GILD;NVO;MDCO;RHHBY;GMED;TEVA;BDX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 15, 2014
05:58 EDTDHRDanaher to host conference call
Subscribe for More Information
05:20 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Danaher has entered into a definitive transaction agreement with Nobel Biocare Holding AG pursuant to which Danaher or one of its direct or indirect subsidiaries will commence a tender offer for all publicly held registered shares of Nobel Biocare in an all-cash transaction valued at approximately $2.2B. The deal is expected to widen Danaher's market presence in the global dental industry and allow Nobel Biocare to accelerate its strategic objectives and future growth. Under the terms of the transaction agreement, Danaher will commence a voluntary all-cash public tender offer of CHF 17.10 per Nobel Biocare share to purchase all of Nobel Biocare's publicly held registered shares. The pre-announcement of the public tender offer is published today. The offer prospectus is expected to be published on or around October 1 and the offer period during which Nobel Biocare shareholders may tender their registered shares is expected to start on or around October 16. In 2013, Nobel Biocare generated annual revenues of approximately $750M. Nobel Biocare would become part of Danaher's $2.2B Dental segment and complements Danaher's position in the implant industry. The Nobel Biocare board has recommended that Nobel Biocare shareholders accept and tender their shares into the offer, which represents a premium of approximately 23% to Nobel Biocare's closing price on July 28, the day before market speculation began regarding a potential sale of the company, or 28% on the basis of the 60 day volume-weighted average price on that date. The offer is expected to be completed in late 2014 or early 2015.
05:17 EDTDHRDanaher to acquire Nobel Biocare Holding for CHF 17.10 per share
Subscribe for More Information
September 12, 2014
14:56 EDTGILDGilead mentioned cautiously at ISI Group
12:12 EDTMDCOThe Medicines Co. to host conference call
Subscribe for More Information
09:01 EDTTEVATeva to present Copaxone gene expression analysis
Subscribe for More Information
08:06 EDTTEVATeva presents new clinical safety data in RRMS patients treated with Laquinimod
Teva (TEVA) and Active Biotech (ACTI) announced new follow-up data evaluating the clinical safety of laquinimod in patients with relapsing-remitting multiple sclerosis, or RRMS, who were treated with laquinimod in Phase II, Phase III and open-label extension studies for two or more years. The pooled safety analysis of the Phase II LAQ/5063 and the Phase III ALLEGRO and BRAVO extension studies supports findings observed in the core studies where currently identified risks were observed within the first months of laquinimod treatment. In the pooled safety analysis, rates of adverse events, or AEs, and serious AEs were lower in the open-label extensions than in the core studies and less than three percent of patients discontinued treatment due to AEs during these extensions. Additionally, shifts to potentially significant laboratory values were considerably lower in patients exposed to at least two years of laquinimod.
08:03 EDTTEVATeva, Active Biotech present laquinimod follow-up data
Subscribe for More Information
September 11, 2014
17:12 EDTNVONovo Nordisk Saxenda receives positive 14-1 vote in favor of approval from FDA
Subscribe for More Information
11:58 EDTGILDStocks with call strike movement; DDD GILD
Subscribe for More Information
09:31 EDTTEVATeva announces new data from Phase IIIb GLACIER study
Subscribe for More Information
07:31 EDTNVOFDA Endocrinologic and Metabolic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
07:19 EDTGMEDGlobus Medical reiterated as top pick at Piper Jaffray
Piper Jaffray reiterates Globus Medical as a top pick and raised its price target for shares to $28 from $26. Piper views the stock's valuation as among the most compelling in its coverage universe. It believes Globus' underlying business is solid and reiterates an Overweight rating on the stock. JMP Securities this morning initiated Globus Medical with an Outperform rating and $25 price target.
06:24 EDTGMEDGlobus Medical initiated with an Outperform at JMP Securities
Subscribe for More Information
03:27 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
September 10, 2014
14:25 EDTTEVATeva Canada announces launch of generic version of Cipralex
Subscribe for More Information
13:04 EDTRHHBYRoche unit receives orphan status for lung cancer mutation drug
Subscribe for More Information
11:06 EDTNVOHigh option volume stocks
Subscribe for More Information
September 9, 2014
12:46 EDTNVONovo Nordisk weight loss drug helped people get thinner, Bloomberg reports
Subscribe for More Information
09:34 EDTGILDGilead recently started cutting Sovaldi pricing by 8%, says Cleveland Research
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use